These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6200390)

  • 61. Scheduling-dependent interaction for the combination of cytosine arabinoside and daunorubicin on HL-60 cells.
    Bernabei PA; Rombolà G; Saccardi R; Bezzini R; Santini V; Pifferi C; Gattei V; Ferrini PR
    Haematologica; 1988; 73(6):466-70. PubMed ID: 3148508
    [No Abstract]   [Full Text] [Related]  

  • 62. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
    Sonneveld P; Nooter K
    Br J Haematol; 1990 Jun; 75(2):208-11. PubMed ID: 2372507
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction.
    Leyden M; Manoharan A; Boyd A; Cheng ZM; Sullivan J
    Br J Haematol; 1984 Jun; 57(2):301-7. PubMed ID: 6587903
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid Remission Induction and Improved Disease Free Survival in Acute Myeloid Leukaemia Using Daunorubicin, ARA-C, and CCNU.
    Barrett AJ; Treleaven JG; Samson DM; Evans M; Gaminara E; Foadi M; McCarthy DM
    Leuk Lymphoma; 1990; 3(2):139-44. PubMed ID: 27457300
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study.
    Dunton SF; Nitschke R; Spruce WE; Bodensteiner J; Krous HF
    Cancer; 1986 Mar; 57(6):1083-8. PubMed ID: 3455842
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical Practice.
    Curtis JE; Hao Y; Messner HA; Lipton JH; Lowsky R; Quirt IC; Sturgeon JF; Zanke B; Keating A; Minden MD
    Hematology; 2000; 5(3):177-187. PubMed ID: 11399613
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Clinical studies and immunology in acute myeloid leukemia during chemo-immunotherapy].
    Lutz D
    Onkologie; 1981 Aug; 4(4):202-12. PubMed ID: 7029383
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia.
    Santini V; Bernabei PA; Silvestro L; Dal Pozzo O; Bezzini R; Viano I; Gattei V; Saccardi R; Ferrini PR
    Hematol Oncol; 1989; 7(4):287-93. PubMed ID: 2737608
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Too much ara-C? Not enough daunorubicin?
    Feldman EJ
    Blood; 2011 Feb; 117(8):2299-300. PubMed ID: 21350058
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Natural selection for imprecise vertical transmission in host-microbiota systems.
    Bruijning M; Henry LP; Forsberg SKG; Metcalf CJE; Ayroles JF
    Nat Ecol Evol; 2022 Jan; 6(1):77-87. PubMed ID: 34949814
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
    Holowiecki J; Rudzka E; Jarczok K; Holowiecka B; Krawczyk M; Duraj M; Japa J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(6):792-7. PubMed ID: 6200390
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.